ADCT
ADC Therapeutics Posts Strong Q1 2026 Results, Eyes Further Growth Opportunities
ADC Therapeutics, a biotechnology company focused on the development and commercialization of innovative cancer therapies, today reported strong financial results for the first quarter of 2026. The company's Q1 2026 earnings conference call, held on May 4, 2026, provided valuable insights into its operational performance and recent business